ACTIVE LEARNING TEMPLATE: Medication Dornase alfa Mucolytic CATEGORY CLASS MEDICATION REVIEW MODULE CHAPTER PURPOSE OF MEDICATION Expected Pharmacological Action Aids in the clearance of bronchial secretions by digesting neutrophil DNA deposited in the pulmonary mucosa reducing viscosity of sputum. Therapeutic Use Decreased infection rates and improved pulmonary function. Complications Hepatic and renal impairment. Contraindications/Precautions -Pregnancy risk category B. -Contraindicated if allergy to Chinese Hamster Ovary cell products. -Use cautiously in children incidence of cough, rhinitis and rash increased. Interactions none Medication Administration Inhalant Nursing Interventions -Assess vital signs and respiratory rate, amount and color of sputum, dyspnea periodically throughout therapy. -Incidence of cough,rash and rhinitis is greater in children under 5 yo. Client Education Evaluation of Medication Effectiveness Improvement in pulmonary function usually within 3 days to 2 weeks and reduction in frequency of infections requiring parenteral antibiotics in patients with CF Instruct client/family to take at the same time each day. If a dose is missed, take as soon as possible. -Emphasize importance of continuing other medications for CF while using dornase alfa

ATI Medication Template Dornase Alfa

Related Documents

Description

Related Documents

Want to Download This Document?

Free up your schedule!

Take 5 seconds to unlock